Association of amyloid pathology with myelin alteration in preclinical Alzheimer disease

JAMA Neurology

Volumn 74, Issue 1, 2017, Pages 41-49

  Dean, Douglas C ^a   Hurley, Samuel A ^b   Kecskemeti, Steven R ^a   O'Grady, J Patrick ^c   Canda, Cristybelle ^c   Davenport Sis, Nancy J ^c   Carlsson, Cynthia M ^c,d   Zetterberg, Henrik ^e,f   Blennow, Kaj ^e   Asthana, Sanjay ^c,d   Sager, Mark A ^c   Johnson, Sterling C ^c,d   Alexander, Andrew L ^a,c   Bendlin, Barbara B ^d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; MYELIN; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; WATER;

ADULT; AGE; AGED; ALZHEIMER DISEASE; APOE EPSILON4 GENE; ARTICLE; COHORT ANALYSIS; CORPUS CALLOSUM; FAMILY HISTORY; FEMALE; FRONTAL LOBE; GENETIC RISK; HUMAN; LUMBAR PUNCTURE; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; WHITE MATTER; AMYLOID PLAQUE; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; DISEASE COURSE; GENETICS; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; MYELIN SHEATH; PATHOLOGY; PHOSPHORYLATION; STATISTICS;

AGE FACTORS; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; BIOMARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYELIN SHEATH; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PLAQUE, AMYLOID; STATISTICS AS TOPIC; TAU PROTEINS; WATER;

EID: 85011372928     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.3232     Document Type: Article

References (40)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580): 353-356.
2. Bartzokis G, Lu PH, Mintz J. Human brain myelination and amyloid beta deposition in Alzheimer's disease. Alzheimers Dement. 2007;3 (2):122-125.
3. Haight TJ, Landau SM, Carmichael O, Schwarz C, DeCarli C, JagustWJ; Alzheimer's Disease Neuroimaging Initiative. Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. JAMA Neurol. 2013;70(8):1039-1045.
4. Bendlin BB, Carlsson CM, Johnson SC, et al. CSF t-tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease. PLoS One. 2012;7(6):e37720.
5. Bartzokis G. Alzheimer's disease as homeostatic responses to age-relatedmyelin breakdown. Neurobiol Aging. 2011;32(8):1341-1371.
6. Roher AE,Weiss N, Kokjohn TA, et al. Increased A β peptides and reduced cholesterol andmyelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry. 2002;41(37): 11080-11090.
7. Zetterberg H,Wahlund L-O, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett. 2003;352(1):67-69.
8. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;2(10): 605-613.
9. Flood DG, Marek GJ, Williams M. Developing predictive CSF biomarkers-A challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. Biochem Pharmacol. 2011;81 (12):1422-1434.
10. Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry. 2004;9(7):705-710.
11. Glodzik L, de Santi S, Tsui WH, et al. Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. Neurobiol Aging. 2011;32(12):2131-2141.
12. Jones DK, Knösche TR, Turner R. White matter integrity, fiber count, and other fallacies: the do's and dont's of diffusion MRI. Neuroimage. 2013;73: 239-254.
13. Bartzokis G. Age-relatedmyelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging. 2004;25(1):5-18.
14. MacKay A, Whittall K, Adler J, Li D, Paty D, Graeb D. In vivo visualization ofmyelin water in brain by magnetic resonance. Magn Reson Med. 1994;31(6):673-677.
15. Deoni SCL, Rutt BK, Arun T, Pierpaoli C, Jones DK. Gleaning multicomponent T1 and T2 information from steady-state imaging data. Magn Reson Med. 2008;60(6):1372-1387.
16. Blennow K, Hampel H,Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer's disease. Nat Rev Neurol. 2010;6(3):131-144.
17. Sager MA, Hermann B, La Rue A. Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer Prevention. J Geriatr Psychiatry Neurol. 2005;18(4):245-249.
18. Deoni SCL, Matthews L, Kolind SH. One component? two components? three? the effect of including a nonexchanging "free" water component in multicomponent driven equilibrium single pulse observation of T1 and T2. Magn Reson Med. 2013; 70(1):147-154.
19. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
20. Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71(10): 1282-1289.
21. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7(3):137-152.
22. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014. http://www.R-project.org. Accessed April 20, 2016.
23. Bendlin BB, Fitzgerald ME, RiesML, et al. White matter in aging and cognition: a cross-sectional study of microstructure in adults aged eighteen to eighty-three. Dev Neuropsychol. 2010;35(3):257-277.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57(1):289-300. https://www.jstor.org/stable/2346101. Accessed October 16, 2015.
25. MacKay A, Laule C, Vavasour I, Bjarnason T, Kolind S, Mädler B. Insights into brain microstructure from the T2 distribution. Magn Reson Imaging. 2006;24(4):515-525.
26. Bartzokis G. Quadratic trajectories of brain myelin content: unifying construct for neuropsychiatric disorders. Neurobiol Aging. 2004; 25(1):49-62.
27. Madsen SK, Ho AJ, Hua X, et al; Alzheimer's Disease Neuroimaging Initiative. 3D maps localize caudate nucleus atrophy in 400 Alzheimer's disease, mild cognitive impairment, and healthy elderly subjects. Neurobiol Aging. 2010;31(8):1312-1325.
28. Bartzokis G, Lu PH, Mintz J. Quantifying age-relatedmyelin breakdown with MRI: novel therapeutic targets for preventing cognitive decline and Alzheimer's disease. J Alzheimers Dis. 2004;6 (6)(suppl):53-59.
29. Deoni SCL, Dean DC III, O'Muircheartaigh J, Dirks H, Jerskey BA. Investigating white matter development in infancy and early childhood using myelin water faction and relaxation time mapping. Neuroimage. 2012;63(3):1038-1053.
30. Dean DC III, O'Muircheartaigh J, Dirks H, et al. Characterizing longitudinal white matter development during early childhood. Brain Struct Funct. 2015;220(4):1921-1933.
31. Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. Brain. 2015;138(pt 10):2814-2833.
32. Giedd JN, Blumenthal J, Jeffries NO, et al. Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci. 1999;2(10): 861-863.
33. Liao M-C, Ahmed M, Smith SO, Van Nostrand WE. Degradation of amyloid beta protein by purifiedmyelin basic protein. J Biol Chem. 2009; 284(42):28917-28925.
34. Hoos MD, Ahmed M, Smith SO, Van Nostrand WE.Myelin basic protein binds to and inhibits the fibrillar assembly of Aβ42 in vitro. Biochemistry. 2009;48(22):4720-4727.
35. Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging. 2003;24(8):1079-1085.
36. Desai MK, Sudol KL, Janelsins MC, Mastrangelo MA, FrazerME, BowersWJ. Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brainmyelination patterns prior to appearance of amyloid and tau pathology. Glia. 2009;57(1):54-65.
37. Hurley SA, Mossahebi PM, Samsonov AA. Multicomponent relaxometry (mcDESPOT) in the shaking pup model of dysmyelination. Paper presented at: International Society forMagnetic Resonance in Medicine 2010 Annual Meeting; May 6, 2010; Stockholm, Sweden. http://cds.ismrm .org/protected/10MProceedings/files/4516-88.pdf. Accessed March 15, 2016.
38. Kitzler HH, Su J, Zeineh M, et al. Deficient MWF mapping in multiple sclerosis using 3D whole-brain multi-component relaxation MRI. Neuroimage. 2012;59(3):2670-2677.
39. Kolind S, Matthews L, Johansen-Berg H, et al. Myelin water imaging reflects clinical variability in multiple sclerosis. Neuroimage. 2012;60(1):263-270.
40. Spader HS, Ellermeier A, O'Muircheartaigh J, et al. Advances inmyelin imaging with potential clinical application to pediatric imaging. Neurosurg Focus. 2013;34(4):E9.